Literature DB >> 22342098

Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation therapy.

Tejpal Gupta1, Rakesh Jalali, Savita Goswami, Vimoj Nair, Aliasgar Moiyadi, Sridhar Epari, Rajiv Sarin.   

Abstract

PURPOSE: To report on acute toxicity, longitudinal cognitive function, and early clinical outcomes in children with average-risk medulloblastoma. METHODS AND MATERIALS: Twenty children ≥ 5 years of age classified as having average-risk medulloblastoma were accrued on a prospective protocol of hyperfractionated radiation therapy (HFRT) alone. Radiotherapy was delivered with two daily fractions (1 Gy/fraction, 6 to 8 hours apart, 5 days/week), initially to the neuraxis (36 Gy/36 fractions), followed by conformal tumor bed boost (32 Gy/32 fractions) for a total tumor bed dose of 68 Gy/68 fractions over 6 to 7 weeks. Cognitive function was prospectively assessed longitudinally (pretreatment and at specified posttreatment follow-up visits) with the Wechsler Intelligence Scale for Children to give verbal quotient, performance quotient, and full-scale intelligence quotient (FSIQ).
RESULTS: The median age of the study cohort was 8 years (range, 5-14 years), representing a slightly older cohort. Acute hematologic toxicity was mild and self-limiting. Eight (40%) children had subnormal intelligence (FSIQ <85), including 3 (15%) with mild mental retardation (FSIQ 56-70) even before radiotherapy. Cognitive functioning for all tested domains was preserved in children evaluable at 3 months, 1 year, and 2 years after completion of HFRT, with no significant decline over time. Age at diagnosis or baseline FSIQ did not have a significant impact on longitudinal cognitive function. At a median follow-up time of 33 months (range, 16-58 months), 3 patients had died (2 of relapse and 1 of accidental burns), resulting in 3-year relapse-free survival and overall survival of 83.5% and 83.2%, respectively.
CONCLUSION: HFRT without upfront chemotherapy has an acceptable acute toxicity profile, without an unduly increased risk of relapse, with preserved cognitive functioning in children with average-risk medulloblastoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22342098     DOI: 10.1016/j.ijrobp.2011.10.037

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies.

Authors:  Abhishek Chatterjee; Madan Maitre; Archya Dasgupta; Epari Sridhar; Tejpal Gupta
Journal:  Methods Mol Biol       Date:  2022

2.  Neurocognitive function and survival in children with average-risk medulloblastoma treated with hyperfractionated radiation therapy alone: Long-term mature outcomes of a prospective study.

Authors:  Tejpal Gupta; Babusha Kalra; Savita Goswami; Jayita Deodhar; Pallavi Rane; Sridhar Epari; Aliasgar Moiyadi; Archya Dasgupta; Abhishek Chatterjee; Girish Chinnaswamy
Journal:  Neurooncol Pract       Date:  2022-03-13

3.  Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique.

Authors:  N Patrik Brodin; Per Munck af Rosenschöld; Malin Blomstrand; Anne Kiil-Berthlesen; Christian Hollensen; Ivan R Vogelius; Birgitta Lannering; Søren M Bentzen; Thomas Björk-Eriksson
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

4.  Critical combinations of radiation dose and volume predict intelligence quotient and academic achievement scores after craniospinal irradiation in children with medulloblastoma.

Authors:  Thomas E Merchant; Jane E Schreiber; Shengjie Wu; Renin Lukose; Xiaoping Xiong; Amar Gajjar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-08-23       Impact factor: 7.038

5.  The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas.

Authors:  Cailei Zhao; Qian Chen; Chunde Li; Jian Yang; Cong Li; Yangyang Zhou; Jianxiang Liao
Journal:  Neurol Sci       Date:  2018-04-10       Impact factor: 3.307

Review 6.  Indian data on central nervous tumors: A summary of published work.

Authors:  Archya Dasgupta; Tejpal Gupta; Rakesh Jalali
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

7.  Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma.

Authors:  Tejpal Gupta; Sarthak Mohanty; Sadhana Kannan; Rakesh Jalali
Journal:  Neurooncol Pract       Date:  2014-08-02

Review 8.  Core deficits and quality of survival after childhood medulloblastoma: a review.

Authors:  Mathilde Chevignard; Hugo Câmara-Costa; François Doz; Georges Dellatolas
Journal:  Neurooncol Pract       Date:  2016-08-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.